Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.
Bottom Line: However, the majority of patients does not recur and might thus be overtreated with adjuvant systemic therapy.We investigated whether the 70-gene MammaPrint signature identifies HER-2-positive patients with favourable outcome. in all, 168 T1-3, N0-1, HER-2-positive patients were identified from a pooled database, classified by the 70-gene signature as good or poor prognosis, and correlated with long-term outcome.The 70-gene signature classified 20 (22%) patients as good prognosis, with 10-year distant disease-free survival (DDFS) of 84%, compared with 69 (78%) poor prognosis patients with 10-year DDFS of 55%.
Affiliation: Division of Diagnostic Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam NL-1066CX, The Netherlands.Show MeSH
Related in: MedlinePlus
Mentions: In the more heterogeneously treated group of all 168 patients, including 79 patients treated with adjuvant chemotherapy or trastuzumab, the univariate HR for good vs poor prognosis by the 70-gene signature for 10-year DDFS was 4.6 (1.1–19.2, P=0.034). For BCSS, the HR was 4.2 (1.0–17.5, P=0.047). The Kaplan–Meier survival curves for this group are shown in Figure 2.
Affiliation: Division of Diagnostic Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam NL-1066CX, The Netherlands.